Insmed 'hopeful' over inhaled amikacin but share price continues nose dive
This article was originally published in Scrip
Executive Summary
Insmed said it is hopeful that it can resume the Phase III trial of its lead candidate Arikace (liposomal amikacin for inhalation) during the fourth quarter of the year, following a US FDA decision to place a clinical hold on the programme at the start of August. The agency based its decision on an initial review of the interim results of a long-term rat inhalation carcinogenicity study with Arikace, recently reported to the agency by Insmed.